N/A
N=70
Validation of a Novel Device for Screening Patients With Symptoms of Obstructive Sleep Apnea
Sleep Apnea, Obstructive
Bottom Line
View on ClinicalTrials.gov: NCT04121923 ↗Enrolled (actual)
70
Serious AEs
0.0%
Results posted
May 2026
Primary outcome: Primary: To Evaluate the Ability of the Ring-REI Measured by Belun Ring to Gauge the AHI Measured by PSG — 16.2; 18.5 events per hour
Study Design & Population
- Study type
- Interventional
- Phase
- N/A
- Interventions
- Belun Ring Pulse Oximeter (Device)
- Age
- Adult, Older Adult · 18+ yrs
- Sex
- All
- Sponsor
- Belun Technology Company Limited
- Primary completion
- Apr 2019
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY To Evaluate the Ability of the Ring-REI Measured by Belun Ring to Gauge the AHI Measured by PSG |
16.2; 18.5 | — |
Summary
The purpose of this study is to evaluate the sensitivity and specificity of the Belun Ring Pulse Oximetry system for screening of obstructive sleep apnea (OSA) in adults during standard polysomnography sleep study conditions. The primary outcome metric is the Apnea-Hypopnea Index (AHI).
The goal, in its entirety, is to evaluate the performance of the Belun Ring Pulse Oximeter during a standard polysomnography sleep study and its ability to compare to the determined Apnea-Hypopnea Index (AHI) of the subjects. It is expected that the Belun Ring Pulse Oximeter will adequately record SpO2, pulse rate, body position and heart rate variability throughout the duration of the study.
Eligibility Criteria
Inclusion Criteria
- Subject must have the ability to understand and provide written informed consent.
- Subject is 18 to 90 years of age.
- Subject must be willing and able to comply with study procedures and duration.
- Male or female of any race.
Exclusion Criteria
- Subject requires oxygen therapy or noninvasive ventilation.
- Subject has a current diagnosis of chronic obstructive pulmonary disorder (COPD), neuromuscular disease, periodic limb movement, or narcolepsy.
- Compromised circulation, injury, or physical malformation of fingers, toes, hands, ears or forehead/skull or other sensor sites which would limit the ability to test sites needed for the study. (Note: Certain malformations may still allow subjects to participate if the condition is noted and would not affect the particular sites utilized.)
- Subject is on medication known to interfere with heart rate, such as beta blockers, digoxin, or calcium receptor agonists.
- Subjects with severe contact allergies to standard adhesives, latex or other materials found in pulse oximetry sensors, ECG electrodes, respiration monitor electrodes or other medical sensors (self-reported).
- Unwillingness or inability to remove colored nail polish from test digits.
- Other known health condition, which should be considered.
Data sourced from ClinicalTrials.gov (NCT04121923). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.